Volume 10 ; Issue 1 ; in Month : June (2020) Article No : 104
Rehman H and Naveed S

Objective: Delafloxacin is fluoroquinolone antibiotics indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is new addition in the class of fluoroquinolone and shows better results with the pathogen Streptococcus pyogenes, Streptococcus agalactiae, Staphylococcus aureus and Methicillin with both susceptible and resistant conditions. By viewing, the current paper is based on clinical pharmacology and practice of Delafloxacin. Methods: Phase I, II and III clinical trial has published on clinical efficacy and safety. Till phase III clinical trial, there is no significance safety concerns appeared. The article concludes the clinical pharmacology of Delafloxacin include basic mechanism of action, clinical pharmacology including pharmacokinetics and dynamics, clinical Efficacy and indicated the current therapeutic uses and practices. Key Findings: No significant drug interaction has been reported yet and showed good tolerance in phase III clinical trial. Conclusion: Delafloxacin can considered to be the best attractive option for gram positive and expect more usage with new practices and indications in future.

Full Text Attachment

Views : 8      Downloads : 0